Last reviewed · How we verify
Chickenpox Vaccines
This vaccine stimulates the immune system to produce antibodies and cellular immunity against varicella-zoster virus, preventing chickenpox infection.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against varicella-zoster virus, preventing chickenpox infection. Used for Prevention of varicella (chickenpox) in children and adults.
At a glance
| Generic name | Chickenpox Vaccines |
|---|---|
| Sponsor | Southeast University, China |
| Drug class | Live attenuated vaccine or inactivated vaccine |
| Target | Varicella-zoster virus (VZV) glycoproteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Chickenpox vaccines contain live attenuated or inactivated varicella-zoster virus that trains the adaptive immune system to recognize and respond to the pathogen. Upon exposure to wild-type virus, the primed immune response rapidly produces neutralizing antibodies and activates T cells to prevent viral replication and disease manifestation.
Approved indications
- Prevention of varicella (chickenpox) in children and adults
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Myalgia
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |